Publications by authors named "Yasuto Sunahara"
Anorexia nervosa (AN) is an eating disorder characterized by restriction of energy intake leading to a significantly low body weight, and intense fear of gaining weight. Severe electrolyte changes such as hypokalemia and hypophosphatemia; and alterations in water metabolism such as hyponatremia and edema, can occur in patients with AN. Hypokalemia and chronic volume depletion may lead to acute kidney injury (AKI) and chronic kidney disease (CKD).
View Article and Find Full Text PDFIntroduction: A reduced salt intake is a vital lifestyle modification in the management of hypertension. Initiatives aimed at decreasing the intake of salt are based on the preference by humans for a salt taste. Salt intake behavior appears to be affected by the balance between attraction to a low salt taste and aversion to a high salt taste.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers created a mouse model that mimics advanced DKD and found significant tissue damage, inflammation, and high levels of VCAM1 in the kidneys, which reflects the condition in humans.
- * The drug luseogliflozin was shown to improve kidney health by reducing tissue hypoxia and inflammation, highlighting the potential of VCAM1 as a marker and SGLT2 inhibitors as a treatment option for advanced DKD.
Article Synopsis
- Streptozotocin (STZ) is mainly used as an anti-cancer drug for treating neuroendocrine tumors (NETs) but can also cause DNA damage in kidney cells, leading to injury.
- Research showed that this kidney damage is linked to the activation of the p53 signaling pathway and reduced membrane transporters in tubular epithelial cells.
- Treatment with an SGLT2 inhibitor can help protect kidney cells from STZ-induced damage without affecting the drug's effectiveness on pancreatic β-cells, suggesting its potential as a preventative treatment for kidney injury in NET patients.